INSMED Inc Q4 FY2024 earnings call

Key Points

• 2024 was historic for Insmed, with significant milestones like the ASPEN study data for brensocatib in bronchiectasis, TPIP Phase 2 data in PH-ILD, and ARIKAYCE's strong revenue performance.
• 2025 highlights: U.S. launch of brensocatib in Q3, Phase 2 data for TPIP in PAH and brensocatib in CRS without nasal polyps, Phase 3 ENCORE trial for ARIKAYCE in Q1 2026, and planned launches of brensocatib in Europe, U.K., and Japan if approved.
• Brensocatib NDA for bronchiectasis was accepted by the FDA under priority review with a PDUFA date of August 12, 2025.
• TPIP Phase 2 PAH data expected mid-2025, with a large study (102 patients randomized 2:1) and primary endpoint measuring PVR reduction. Phase 3 trials in PH-ILD and PAH are underway.
• ARIKAYCE revenue guidance for 2025 is $405 million to $425 million.

In 2024, Insmed's global net revenue was $363.7 million, reflecting 19% year-over-year growth. Specifically, U.S. net revenue in 2024 was $254.8 million, up 14% compared to 2023. Japan's net revenue was $87.7 million, up 33% year-over-year. Europe and Rest of World net revenue was $21.2 million, up 39% year-over-year. ARIKAYCE had record-setting revenues in 2024, with strong performance across geographic regions.

• ARIKAYCE 2025 revenue guidance: $405 million to $425 million.
• Brensocatib expected U.S. launch in Q3 2025, with pricing and access dynamics to be determined post-launch.
• TPIP Phase 2 PAH data expected mid-2025, with Phase 3 trials in PH-ILD and PAH planned.
• Phase 3 ENCORE trial for ARIKAYCE expected to read out in Q1 2026, potentially expanding the label for MAC lung infection.

• Uncertainties in FDA review process due to potential staffing shortages and challenges in meeting PDUFA dates.
• Market access and payer dynamics that could impact brensocatib's launch and pricing.
• Variability in clinical trial results and execution risks associated with commercial launches of new products.

Q: How is Insmed leveraging market access for brensocatib's launch?

A: Insmed is focusing on market access to ensure a frictionless launch, including a simple prior authorization process and reauthorization. They are willing to do minor contracting and are working on verbal attestation from physicians for initial prescriptions and reauthorization.

Q: On the gene therapy pipeline, specifically DMD, ALS, and Stargardt disease, what are the differentiating factors?

A: For DMD, Insmed is using an AAV9 capsid and MHCK7 promoter with intrathecal delivery, which has shown promising preclinical results. For ALS, there is encouraging preclinical data for both SOD1 and sporadic patients. For Stargardt disease, RNA end joining technology is being used, with preclinical data showing promise.